Username
Password
Home About MTSL
Excerpts
Performance
Subscribe
  Register for a FREE Sample Issue
Hulbert Ranking

Peter Brimelow: 'A detailed review of Medical Technology Stock Letter (like the one we did a couple of years ago) reveals real strengths, as borne out by the fact that it's repeatedly been able to pull itself back into Hulbert's top-performing group in the past, through the incredible feat of registering year-on-year triple-digit gains .'

For full article, click here .
By Peter Brimelow,

Investment Scan

ASCO Abstracts Coming

 


Full article is available only to MTSL subscribers.

 

Biotech Sector Analysis

 

Published 5/8/08:   We would like to point out to subscribers that the annual meeting of the American Society of Clinical Oncology (ASCO) is right around the corner, set to take place May 30 through June 3 in Chicago.  However, as opposed to years past, for the first time the abstracts that are going to be presented at this year’s ASCO meeting are going to be made available to everyone—not just ASCO members—ahead of the meeting.  This should help greatly in leveling the playing field by not allowing a select few to trade on information that not everyone has access to. 

 

MTSL In The News

Portfolio Performance

May 2, 2008 through May 8, 2008:

Model Portfolio -  Down 4.1%
Trader's Portfolio - Down 7.0%

S&P500  - Down 0.8%
Nasdaq  - Down 1.2%

 

 


MTSL & You
We provide experienced analysis to find sustainable values in the risky field of biotechnology investing. Timely information, clear investment advice, an industry-wide view, and top-rated performance keeps us at the forefront of all investment letters, and makes MTSL the premier tool for biotech investing.
  John T. McCamant
Editor
  Jim McCamant
Editor at Large
John's Calendar
4/10/08 - 5:00pm ET
John McCamant
interview with Pimm Foxx on
Bloomberg Television on Takeda buys MLNM for $8.8 billion! Who's next?
E-mail | Refund Policy | Privacy
©2008 Piedmont Venture Group. All Rights Reserved.
   Website Design by ZINFI